The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).

Recombinant Therapeutic Antibodies and Proteins Market

The global market for Recombinant Therapeutic Antibodies and Proteins was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.

This report aims to provide a comprehensive presentation of the global market for Recombinant Therapeutic Antibodies and Proteins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Therapeutic Antibodies and Proteins.

The Recombinant Therapeutic Antibodies and Proteins market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recombinant Therapeutic Antibodies and Proteins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Recombinant Therapeutic Antibodies and Proteins companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Recombinant Therapeutic Antibodies and Proteins Market Report

Report Metric	Details
Report Name	Recombinant Therapeutic Antibodies and Proteins Market
Accounted market size in 2017	US$ 92.5 billion
CAGR	11.2%
Base Year	2017
Segment by Type	Plasma Protein Fusion Proteins Monoclonal Antibodies Hormones Enzyme Coagulation Factors Others
Segment by Application	Oncology Hematology Immunology Endocrinology Infectious Disease Cardiovascular Disease Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Abbott, Amgen, Biogen, Eli Lilly, Roche, Johnson and Johnson, Merck, Novo Nordisk, Pfizer, Sanofi
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Therapeutic Antibodies and Proteins company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Recombinant Therapeutic Antibodies and Proteins Market report?

Ans: The main players in the Recombinant Therapeutic Antibodies and Proteins Market are Abbott, Amgen, Biogen, Eli Lilly, Roche, Johnson and Johnson, Merck, Novo Nordisk, Pfizer, Sanofi

What are the Application segmentation covered in the Recombinant Therapeutic Antibodies and Proteins Market report?

Ans: The Applications covered in the Recombinant Therapeutic Antibodies and Proteins Market report are Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, Others

What are the Type segmentation covered in the Recombinant Therapeutic Antibodies and Proteins Market report?

Ans: The Types covered in the Recombinant Therapeutic Antibodies and Proteins Market report are Plasma Protein, Fusion Proteins, Monoclonal Antibodies, Hormones, Enzyme, Coagulation Factors, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Plasma Protein

1.2.3 Fusion Proteins

1.2.4 Monoclonal Antibodies

1.2.5 Hormones

1.2.6 Enzyme

1.2.7 Coagulation Factors

1.2.8 Others

1.3 Market by Application

1.3.1 Global Recombinant Therapeutic Antibodies and Proteins Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Oncology

1.3.3 Hematology

1.3.4 Immunology

1.3.5 Endocrinology

1.3.6 Infectious Disease

1.3.7 Cardiovascular Disease

1.3.8 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Perspective (2020-2031)

2.2 Global Recombinant Therapeutic Antibodies and Proteins Growth Trends by Region

2.2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Region (2020-2025)

2.2.3 Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Region (2026-2031)

2.3 Recombinant Therapeutic Antibodies and Proteins Market Dynamics

2.3.1 Recombinant Therapeutic Antibodies and Proteins Industry Trends

2.3.2 Recombinant Therapeutic Antibodies and Proteins Market Drivers

2.3.3 Recombinant Therapeutic Antibodies and Proteins Market Challenges

2.3.4 Recombinant Therapeutic Antibodies and Proteins Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Revenue

3.1.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Revenue (2020-2025)

3.1.2 Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Players (2020-2025)

3.2 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Recombinant Therapeutic Antibodies and Proteins Revenue

3.4 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio

3.4.1 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Recombinant Therapeutic Antibodies and Proteins Revenue in 2024

3.5 Global Key Players of Recombinant Therapeutic Antibodies and Proteins Head office and Area Served

3.6 Global Key Players of Recombinant Therapeutic Antibodies and Proteins, Product and Application

3.7 Global Key Players of Recombinant Therapeutic Antibodies and Proteins, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Type

4.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Type (2020-2025)

4.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Type (2026-2031)

5 Recombinant Therapeutic Antibodies and Proteins Breakdown Data by Application

5.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Application (2020-2025)

5.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size (2020-2031)

6.2 North America Recombinant Therapeutic Antibodies and Proteins Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2020-2025)

6.4 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size (2020-2031)

7.2 Europe Recombinant Therapeutic Antibodies and Proteins Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2020-2025)

7.4 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size (2020-2031)

8.2 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2020-2025)

8.4 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size (2020-2031)

9.2 Latin America Recombinant Therapeutic Antibodies and Proteins Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2020-2025)

9.4 Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size (2020-2031)

10.2 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2020-2025)

10.4 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Abbott

11.1.1 Abbott Company Details

11.1.2 Abbott Business Overview

11.1.3 Abbott Recombinant Therapeutic Antibodies and Proteins Introduction

11.1.4 Abbott Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

11.1.5 Abbott Recent Development

11.2 Amgen

11.2.1 Amgen Company Details

11.2.2 Amgen Business Overview

11.2.3 Amgen Recombinant Therapeutic Antibodies and Proteins Introduction

11.2.4 Amgen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

11.2.5 Amgen Recent Development

11.3 Biogen

11.3.1 Biogen Company Details

11.3.2 Biogen Business Overview

11.3.3 Biogen Recombinant Therapeutic Antibodies and Proteins Introduction

11.3.4 Biogen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

11.3.5 Biogen Recent Development

11.4 Eli Lilly

11.4.1 Eli Lilly Company Details

11.4.2 Eli Lilly Business Overview

11.4.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Introduction

11.4.4 Eli Lilly Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

11.4.5 Eli Lilly Recent Development

11.5 Roche

11.5.1 Roche Company Details

11.5.2 Roche Business Overview

11.5.3 Roche Recombinant Therapeutic Antibodies and Proteins Introduction

11.5.4 Roche Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

11.5.5 Roche Recent Development

11.6 Johnson and Johnson

11.6.1 Johnson and Johnson Company Details

11.6.2 Johnson and Johnson Business Overview

11.6.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Introduction

11.6.4 Johnson and Johnson Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

11.6.5 Johnson and Johnson Recent Development

11.7 Merck

11.7.1 Merck Company Details

11.7.2 Merck Business Overview

11.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Introduction

11.7.4 Merck Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

11.7.5 Merck Recent Development

11.8 Novo Nordisk

11.8.1 Novo Nordisk Company Details

11.8.2 Novo Nordisk Business Overview

11.8.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Introduction

11.8.4 Novo Nordisk Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

11.8.5 Novo Nordisk Recent Development

11.9 Pfizer

11.9.1 Pfizer Company Details

11.9.2 Pfizer Business Overview

11.9.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Introduction

11.9.4 Pfizer Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

11.9.5 Pfizer Recent Development

11.10 Sanofi

11.10.1 Sanofi Company Details

11.10.2 Sanofi Business Overview

11.10.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Introduction

11.10.4 Sanofi Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

11.10.5 Sanofi Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Plasma Protein

Table 3. Key Players of Fusion Proteins

Table 4. Key Players of Monoclonal Antibodies

Table 5. Key Players of Hormones

Table 6. Key Players of Enzyme

Table 7. Key Players of Coagulation Factors

Table 8. Key Players of Others

Table 9. Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 11. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2020-2025) & (US$ Million)

Table 12. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Region (2020-2025)

Table 13. Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 14. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Region (2026-2031)

Table 15. Recombinant Therapeutic Antibodies and Proteins Market Trends

Table 16. Recombinant Therapeutic Antibodies and Proteins Market Drivers

Table 17. Recombinant Therapeutic Antibodies and Proteins Market Challenges

Table 18. Recombinant Therapeutic Antibodies and Proteins Market Restraints

Table 19. Global Recombinant Therapeutic Antibodies and Proteins Revenue by Players (2020-2025) & (US$ Million)

Table 20. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Players (2020-2025)

Table 21. Global Top Recombinant Therapeutic Antibodies and Proteins Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Therapeutic Antibodies and Proteins as of 2024)

Table 22. Ranking of Global Top Recombinant Therapeutic Antibodies and Proteins Companies by Revenue (US$ Million) in 2024

Table 23. Global 5 Largest Players Market Share by Recombinant Therapeutic Antibodies and Proteins Revenue (CR5 and HHI) & (2020-2025)

Table 24. Global Key Players of Recombinant Therapeutic Antibodies and Proteins, Headquarters and Area Served

Table 25. Global Key Players of Recombinant Therapeutic Antibodies and Proteins, Product and Application

Table 26. Global Key Players of Recombinant Therapeutic Antibodies and Proteins, Date of Enter into This Industry

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2020-2025) & (US$ Million)

Table 29. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Type (2020-2025)

Table 30. Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 31. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Type (2026-2031)

Table 32. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2020-2025) & (US$ Million)

Table 33. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Application (2020-2025)

Table 34. Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 35. Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Application (2026-2031)

Table 36. North America Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2020-2025) & (US$ Million)

Table 38. North America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2026-2031) & (US$ Million)

Table 39. Europe Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 40. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2020-2025) & (US$ Million)

Table 41. Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2026-2031) & (US$ Million)

Table 42. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 43. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2020-2025) & (US$ Million)

Table 44. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size by Region (2026-2031) & (US$ Million)

Table 45. Latin America Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2020-2025) & (US$ Million)

Table 47. Latin America Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2026-2031) & (US$ Million)

Table 48. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 49. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2020-2025) & (US$ Million)

Table 50. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size by Country (2026-2031) & (US$ Million)

Table 51. Abbott Company Details

Table 52. Abbott Business Overview

Table 53. Abbott Recombinant Therapeutic Antibodies and Proteins Product

Table 54. Abbott Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025) & (US$ Million)

Table 55. Abbott Recent Development

Table 56. Amgen Company Details

Table 57. Amgen Business Overview

Table 58. Amgen Recombinant Therapeutic Antibodies and Proteins Product

Table 59. Amgen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025) & (US$ Million)

Table 60. Amgen Recent Development

Table 61. Biogen Company Details

Table 62. Biogen Business Overview

Table 63. Biogen Recombinant Therapeutic Antibodies and Proteins Product

Table 64. Biogen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025) & (US$ Million)

Table 65. Biogen Recent Development

Table 66. Eli Lilly Company Details

Table 67. Eli Lilly Business Overview

Table 68. Eli Lilly Recombinant Therapeutic Antibodies and Proteins Product

Table 69. Eli Lilly Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025) & (US$ Million)

Table 70. Eli Lilly Recent Development

Table 71. Roche Company Details

Table 72. Roche Business Overview

Table 73. Roche Recombinant Therapeutic Antibodies and Proteins Product

Table 74. Roche Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025) & (US$ Million)

Table 75. Roche Recent Development

Table 76. Johnson and Johnson Company Details

Table 77. Johnson and Johnson Business Overview

Table 78. Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Product

Table 79. Johnson and Johnson Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025) & (US$ Million)

Table 80. Johnson and Johnson Recent Development

Table 81. Merck Company Details

Table 82. Merck Business Overview

Table 83. Merck Recombinant Therapeutic Antibodies and Proteins Product

Table 84. Merck Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025) & (US$ Million)

Table 85. Merck Recent Development

Table 86. Novo Nordisk Company Details

Table 87. Novo Nordisk Business Overview

Table 88. Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Product

Table 89. Novo Nordisk Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025) & (US$ Million)

Table 90. Novo Nordisk Recent Development

Table 91. Pfizer Company Details

Table 92. Pfizer Business Overview

Table 93. Pfizer Recombinant Therapeutic Antibodies and Proteins Product

Table 94. Pfizer Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025) & (US$ Million)

Table 95. Pfizer Recent Development

Table 96. Sanofi Company Details

Table 97. Sanofi Business Overview

Table 98. Sanofi Recombinant Therapeutic Antibodies and Proteins Product

Table 99. Sanofi Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025) & (US$ Million)

Table 100. Sanofi Recent Development

Table 101. Research Programs/Design for This Report

Table 102. Key Data Information from Secondary Sources

Table 103. Key Data Information from Primary Sources

Table 104. Authors List of This Report

List of Figures

Figure 1. Recombinant Therapeutic Antibodies and Proteins Picture

Figure 2. Global Recombinant Therapeutic Antibodies and Proteins Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Type: 2024 VS 2031

Figure 4. Plasma Protein Features

Figure 5. Fusion Proteins Features

Figure 6. Monoclonal Antibodies Features

Figure 7. Hormones Features

Figure 8. Enzyme Features

Figure 9. Coagulation Factors Features

Figure 10. Others Features

Figure 11. Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2020-2031) & (US$ Million)

Figure 12. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Application: 2024 VS 2031

Figure 13. Oncology Case Studies

Figure 14. Hematology Case Studies

Figure 15. Immunology Case Studies

Figure 16. Endocrinology Case Studies

Figure 17. Infectious Disease Case Studies

Figure 18. Cardiovascular Disease Case Studies

Figure 19. Others Case Studies

Figure 20. Recombinant Therapeutic Antibodies and Proteins Report Years Considered

Figure 21. Global Recombinant Therapeutic Antibodies and Proteins Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 22. Global Recombinant Therapeutic Antibodies and Proteins Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 23. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Region: 2024 VS 2031

Figure 24. Global Recombinant Therapeutic Antibodies and Proteins Market Share by Players in 2024

Figure 25. Global Top Recombinant Therapeutic Antibodies and Proteins Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Therapeutic Antibodies and Proteins as of 2024)

Figure 26. The Top 10 and 5 Players Market Share by Recombinant Therapeutic Antibodies and Proteins Revenue in 2024

Figure 27. North America Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. North America Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2020-2031)

Figure 29. United States Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Canada Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Europe Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Europe Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2020-2031)

Figure 33. Germany Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. France Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. U.K. Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Italy Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Russia Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Nordic Countries Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Market Share by Region (2020-2031)

Figure 41. China Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Japan Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. South Korea Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. India Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Australia Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Latin America Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Latin America Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2020-2031)

Figure 49. Mexico Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Brazil Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Market Share by Country (2020-2031)

Figure 53. Turkey Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 55. UAE Recombinant Therapeutic Antibodies and Proteins Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 56. Abbott Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

Figure 57. Amgen Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

Figure 58. Biogen Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

Figure 59. Eli Lilly Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

Figure 60. Roche Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

Figure 61. Johnson and Johnson Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

Figure 62. Merck Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

Figure 63. Novo Nordisk Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

Figure 64. Pfizer Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

Figure 65. Sanofi Revenue Growth Rate in Recombinant Therapeutic Antibodies and Proteins Business (2020-2025)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions